Trevi Therapeutics Shares Q3 2025 Financial Results
Trevi Therapeutics, Inc. (NASDAQ: TRVI) has recently communicated its financial results for the third quarter of 2025, revealing a robust position with $194.9 million in cash, cash equivalents, and marketable securities. This strong financial footing assures the company’s cash runway comfortably extending into 2028.
The company is gearing up to kick off a comprehensive Phase 3 program targeting chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF), slated for the first half of 2026. President and CEO Jennifer Good expressed enthusiasm over the current progress following positive clinical data. The organization is committed to advancing its research and aims for a successful End-of-Phase 2 meeting with the FDA during the fourth quarter.
Chronic Cough in IPF and Key Developments
Trevi’s proprietary drug, Haduvio™ (oral nalbuphine ER), designed to treat chronic cough in IPF patients and those with refractory chronic cough (RCC), has shown promising results thus far. Trevi is set to request an End-of-Phase 2 meeting in the coming months, aiming to reinforce its commitment to advancing crucial studies.
A significant highlight for the company includes the completion of a Phase 1 respiratory function and safety trial named TIDAL. Encouragingly, the safety review committee did not find any adverse safety signals for the sentinel cohort of patients, allowing for continued enrollment. The company anticipates concluding this study towards the end of the current quarter, and the data will be vital for the FDA meeting package.
Recent Clinical Trials and Achievements
Trevi Therapeutics recently completed a Phase 1 study evaluating drug-drug interactions involving nalbuphine ER and antifibrotic therapies like pirfenidone and nintedanib. The findings indicated that the combination did not yield any clinically meaningful pharmacokinetic changes, providing further validation for the drug’s safety.
Moreover, Trevi presented topline results from its Phase 2b CORAL trial during a well-attended conference meeting. This indicates the continuous commitment to transparency and engagement with the medical community, showcasing the promising impacts of their investigational therapies.
Plans for Refractory Chronic Cough
In addition to its offerings for IPF patients, Trevi Therapeutics is also preparing to initiate a Phase 2b study for refractory chronic cough. Following the encouraging results from the Phase 2a RIVER trial, the company is confident in moving forward with its comprehensive clinical strategy.
Results from earlier RIVER trial data have been shared at key industry conferences, underlining the company’s efforts to disseminate findings widely and foster collaboration with medical experts. This solidifies Trevi's commitment to tackling the unmet needs in chronic cough therapies.
Financial Overview and Operational Insights
Trevi has laid out a clear financial picture: R&D expenses for the recent quarter were reported at $10.1 million, indicating a drop from $11.2 million during the prior period due to reduced clinical development expenses. However, increases in the costs associated with successfully completed Phase 1 studies evince ongoing investments towards innovation.
General and Administrative (G&A) expenses rose to $3.8 million, reflecting additional expenditures associated with professional services and supporting personnel costs to ensure that the company can meet its ambitious growth targets.
In terms of overall performance, Trevi reported a net loss of $11.8 million, a notable improvement from the $13.2 million loss experienced during the same quarter last year—demonstrating effective cost management and a commitment to proactive financial strategies.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is dedicated to researching and developing innovative therapies aimed at chronic cough in IPF and related conditions. The investigational Haduvio™ has emerged as a notable treatment candidate, demonstrating a significant reduction in cough frequency across clinical trials.
With a market opportunity catering to the thousands of patients suffering from chronic cough—many of whom have no viable treatment options—Trevi’s dedication to addressing these pressing healthcare challenges is as acute as ever. They strive to cultivate a therapeutic solution that can enhance patient quality of life across various debilitating conditions, from IPF to refractory chronic cough.
The ongoing journey towards gaining FDA approval serves as an impetus for Trevi as they continue refining their strategic development plans and gathering clinical evidence for therapeutic efficacy. As they prepare for future trials and further corporate growth, Trevi Therapeutics exemplifies the intersection of science and patient advocacy within the biopharmaceutical landscape.
Frequently Asked Questions
What are Trevi Therapeutics' primary goals for 2026?
Trevi aims to initiate a comprehensive Phase 3 program for chronic cough treatment in patients with idiopathic pulmonary fibrosis in 2026.
What financial position does Trevi retain as of Q3 2025?
Trevi ended Q3 2025 with $194.9 million in cash, ensuring a runway into 2028.
What are the recent clinical highlights from Trevi Therapeutics?
Trevi successfully completed a Phase 1 safety study and has concluded significant drug-drug interaction trials for Haduvio.
What is Haduvio expected to address?
Haduvio targets chronic cough conditions in IPF patients and RCC, which currently have no approved treatments.
How does Trevi plan to communicate its findings to stakeholders?
Trevi actively shares clinical trial results at medical conferences and engages with the FDA to ensure transparency and collaboration.
